[1] Hameed A,Brady JJ,Dowling P,et al.Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33-42.[2] Palma BD,Guasco D,Pedrazzoni M,et al.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Leukemia. 2016;30(2): 409-416. [3] Minarik J,Hermanova Z,Petrova P,et al.Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers.Eur J Haematol.2016; 97(2):201-207.[4] Bolzoni M, Storti P, Bonomini S, et al.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol.2013;41(4): 387-397.e1 [5] Graves DT,Alshabab A,Albiero ML,et al.Osteocytes play an important role in experimental periodontitis in healthy and diabetic mice through expression of RANKL.J Clin Periodontol. 2018;45(3):285-292.[6] Delgado-Calle J,Anderson J,Cregor MD,et al.Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.Cancer Res.2016; 76(5):1089-1100.[7] Vallet S, Pozzi S, Patel K, et al.A novel role for CCL3 (MIP-1a) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia.2011;25(7):1174-1181. [8] Wang XT, He YC, Zhou SY, et al.Bone marrow plasma macrophage inflammatory protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: Relationship with bone disease and clinical characteristics.2014;38(5):525-531. [9] Walker RE, Lawson MA, Buckle CH.et al. Myeloma bone disease: pathogenesis, current treatments and future targets.Br Med Bull.2014;111(1):117-138.[10] Colucci S, Brunetti G, Oranger A, et al.Myeloma cells suppress osteoblasts through sclerostin secretion.Blood Cancer J.2011;22(1):1-7.[11] Higgs JT, Lee JH, Wang H.et al. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.Blood Adv.2017;1(25): 2375-2385.[12] Palma BD,Guasco D,Pedrazzoni M,et al.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Leukemia.2016;30(2):409-416.[13] Groeneveldt L,Mein G,Garrod R,et al.A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC Cancer.2013;13(31):1-10.[14] Miceli TS, Colson K, Faiman BM,et al.Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Clin J Oncol Nurs.2011;15 Suppl:9-23.[15] Pagnotti GM,Chan ME,Adler BJ,et al.Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.Bone.2016;90:69-79. [16] Li X, Niu QT, Warmington KS,et al.Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.Endocrinology.2014;155(12):4785-4797.[17] McGrath RP,Kraemer WJ,Vincent BM.et al.Muscle-Strength Is Protective Against Osteoporosis in an Ethnically Diverse Sample of adults.J Strength Cond Res.2017;31(9): 2586-2589.[18] Middleton K,Al-Dujaili S,Mei X,et al.Microfluidic co-culture platform for investigating osteocyte-osteoclast signalling during fluid shearstress mechanostimulation.J Biomech. 2017;59:35-42. [19] Shah KM, Orton P, Mani N,et al. Osteocyte physiology and response to fluid shear stress are impaired following exposure to cobalt and chromium: Implications for bone health following joint replacement.J Orthop Res.2017;35(8):1716-1723. [20] Sartawi Z,Schipani E,Ryan KB, et al.Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair.Pharmacol Res. 2017;125(Pt B):232-245.[21] Meshcheryakova A,Mechtcheriakova D,Pietschmann P.Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential.Expert Opin Ther Targets. 2017;21(7):725-737.[22] Zhang J,Ding C,Meng X,et al.Nitric oxide modulates the responses of osteoclast formation to static magnetic fields. Electromagn Biol Med.2017;13:1-12.[23] Xiao L,Zhu L,Yang S,et al.Different correlation of sphingosine-1-phosphate receptor 1 with receptor activator of nuclear factor kappa B ligand and regulatory T cells in rat periapical lesions.J Endod.2015;41(4):479-486.[24] Kim BJ, Shin KO, Kim H ,et al.The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient.J Endocrinol Invest.2016;39(3):297-303. [25] Yuan M,Chen J,Zeng Z.Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.Mol Med Rep.2016;14(6): 5199-5204.[26] Pitari MR,Rossi M,Amodio N,et al.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Oncotarget.2015;6(29):27343-27358. [27] Kristensen IB,Christensen JH,Lyng MB,et al.Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Leuk Lymphoma.2014; 55(4):911-919.[28] Delgado-Calle J,Arozamena J,Pérez-López J,et al.Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells.Mol Cell Endocrinol. 2013;369(1-2):27-34. [29] 陈少龙,赵良功,滕元君,等.周期性和持续性流体剪切力对成骨细胞OPG、RANKL蛋白表达的影响[J].中国医学物理学杂志, 2015, 32(1):120-123,133. |